Endometriosis: In search of optimal treatment

Minerva Ginecologica

Volumn 62, Issue 1, 2010, Pages 17-31

  Nothnick, W B ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis inducing agents; Aromatase; Endometriosis, therapy; Matrix metalloproteinase; Tumor necrosis factor alpha

Indexed keywords

11BETA (4 ACETYLPHENYL) 17BETA HYDROXY 17ALPHA (1,1,2,2,2 PENTAFLUOROETHYL)ESTRA 4,9 DIEN 3 ONE; ADALIMUMAB; ANASTROZOLE; AROMATASE INHIBITOR; CALCITRIOL; CETRORELIX; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYCLOOXYGENASE 2 INHIBITOR; DANAZOL; ETANERCEPT; ETHINYLESTRADIOL PLUS LEVONORGESTREL; EXEMESTANE; GESTAGEN; GONADORELIN ANTAGONIST; GOSERELIN; INFLIXIMAB; LEFLUNOMIDE; LETROZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METHOTREXATE; MIFEPRISTONE; NAFARELIN ACETATE; NORETHISTERONE ACETATE; ONAPRISTONE; ONERCEPT; PENTOXIFYLLINE; PROGESTERONE RECEPTOR MODULATOR; ROFECOXIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZK 136 799; ZK 98 299;

ANTIANGIOGENIC THERAPY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; ENDOMETRIOSIS; ESTROGEN THERAPY; FEMALE; GASTROINTESTINAL SYMPTOM; HORMONAL THERAPY; HORMONE RECEPTOR INTERACTION; HOT FLUSH; HUMAN; LIBIDO; MULTIPLE CYCLE TREATMENT; NONHUMAN; PELVIS PAIN SYNDROME; PREVALENCE; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; UTERUS SURGERY; VAGINA DISEASE;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; AROMATASE INHIBITORS; ENDOMETRIOSIS; ESTROGEN RECEPTOR MODULATORS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; IMMUNOGLOBULIN G; ISOXAZOLES; NITRILES; PENTOXIFYLLINE; PROGESTERONE; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TRIAZOLES; TUMOR NECROSIS FACTOR DECOY RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952828551     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Halme J, Hammond MG, Hulka JF, Raj SG, Talbert LM. Retrograde menstruation in healthy women and in patients with endometriosis. Obstet Gynecol 1984;64:151-154
2. Liu DTY, Hitchcock A. Endometriosis: Its association with retrograde menstruation, dysmenorrhea, and tubal pathology. Br J Obstet Gynaecol 1986;93:859-886 (Pubitemid 16010438)
3. Abbott JA, Clayton RD, Garry R. The effects and effectiveness of laparoscopic excision of endometriosis: a prospective study with 2-5 year follow-up. Hum Reprod 2003;9:1922-1927 (Pubitemid 37107569)
4. Olive DL, Pritss EA. The treatment of endometriosis. A review of the evidence. Ann NY Acad Sci 2002;955:360-372
5. Montgomery-Rice V. Conventional medical therapies for endometriosis. Ann NY Acad Sci 2002;955:343-352
6. Valle RF, Sciarra JJ. Endometriosis: Treatment strategies. Ann NY Acad Sci 2003;997:229-239
7. Vercellini P, Cortesi I, Crosignani PG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 1997;68:393-401. (Pubitemid 27412901)
8. Felberbaum RE, Diedrich K. Gonadotropin hormone-releasing antagonists: will they replace the agonists? Reprod Biomed Online 2003;6:43-53.
9. Clemens LE, Sitter PK, Stites DP. Mechanism of immunosuppression of progesterone on maternal lymphocyte activation during pregnancy. J Immunol 1979;122:1978-1985
10. Schust DJ, Anderson DJ, Hill JA. Progesterone-induced immunosuppression is not mediated through the progesterone receptor. Hum Reprod 1996;11:980-985
11. Osteen KG, Keller NR, Feltus FA, Meiner MH. Paracrine regulation of matrix metalloproteinase expression in the normal endometrium. Gynecol Obstet Invest 1999;48(Suppl 1):2-13.
12. Hill JA, Barbieri RL, Anderson DJ. Immunosuppressive effects of danazol in vitro. Fertil Steril 1987;48:414-418
13. Mori H, Nakagawa M, Itoh N, Wada K, Tamaya T. Danazol suppresses the production of interleukin-1b and tumor necrosis factor by human monocytes. Am J Reprod Immunol 1990;24:45-50.
14. Ota H, Igarashi S, Hayakawa M, Matsui T, Tanaka H, Tanaka T. Effect of danazol on the immunocompetent cells in the eutopic endometrium in patients with endometriosis: a multicenter cooperative study. Fertil Steril 1996;65:545-551 (Pubitemid 26069110)
15. Wu M-Y, Chao K-H, Chen SU, Chen HF, Yang YS, Huang SC, Ho HN. The suppression of peritoneal cellular immunity in women with endometriosis could be restored after gonadotropin releasing hormone agonist treatment. Am J Reprod Immunol 1996;35:510-516
16. Chen HF, Jeung EB, Stephenson M, Leung PC. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab 1999;84:743-750 (Pubitemid 29075715)
17. Harada T, Enatsu A, Mitsunari M, Nagano Y, Ito M, Tsudo T et al. Role of cytokines in progression of endometriosis. Gynecol Obstet Invest 1999;47(Suppl 1):34-40.
18. Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T. Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. Gynecol Oncol 1994;55:144-148 (Pubitemid 24336135)
19. Ikeda M, Taga M, Kurogi K, Minaguchi H. Gene expression of gonadotropin-releasing hormone, but not its receptor in human endometrium and decidua. Mol Cell Endocrinol 1997;135:165-168 (Pubitemid 28039434)
20. Borroni R, Di Blasio AM, Gaffuri B, Santorsola R, Busacca M, Viganò P et al. Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate. Mol Cell Endocrinol 2000;159:37-43. (Pubitemid 30067638)
21. Adashi EY. Long-term gonadotropin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms. Hum Reprod Update 1994;7:1380-1397
22. Kiesel L, Schweppe KW, Sillem M, Siebzehnrübl E. Should add-back therapy for endometriosis be deferred for optimal results? Br J Obstet Gynaecol 1996;103(Suppl 14):15-17
23. Surrey ES. Add-back therapy and GnRH agonist in the treatment of patients with endometriosis: can a consensus be reached? Add-back consensus Working Group. Fertil Steril 1999;71:420-424
24. Watanabe Y, Nakamura G, Matsuguchi H, Nozaki M, Sano M, Nakano H. Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women. Fertil Steril 1992;58:66-71.
25. Wheeler JM, Knittle JD, Miller JD. Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. Am J Obstet Gynecol 1993;169:26-33.
26. Warnock JK, Bundren JC, Morris DW. Depressive symptoms associated with gonadotropin-releasing hormone agonists. Depress Anxiety 1998;7:171-177
27. Rachman M, Garfield DA, Rachman I, Cohen R. Lupron-induced mania. Biol Psychiatry 1999;45:243-244
28. Kupker W, Felberbaum RE, Krapp M, Schill T, Malik E, Diedrich K. Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online 2002;5:12-16
29. Murphy AA, Zhou MH, Malkapuram S, Santanam N, Parthasarathy S, Sidell N. RU486-induced growth inhibition of human endometrial cells. Fertil Steril 2000;74:1014-1019
30. Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SS. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 1996;65:23-28 (Pubitemid 26006643)
31. Kettel LM. Murphy AA, Morales AJ, Yen SS. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU486). Am J Obstet Gynecol 1998;178:1151-1156
32. Stoeckemann K, Hegele-Hartung C, Chwalisz K. Effects of the progesterone antagonists onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis in intact rats. Hum Reprod 1995;10:3264-3271 (Pubitemid 26027277)
33. Fuhrmann U, Hess-Stummp H, Cleve A, Neef G, Schwede W, Hoffmann J et al. Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Medicinal Chemistry 2000;43:5010-5016 (Pubitemid 32039022)
34. Slayden OD, Chwalisz K, Brenner RM. Reversible suppression of menstruation with progesterone antagonists in rhesus macaques. Hum Reprod 2001;8:1562-1574 (Pubitemid 32761732)
35. Bruner-Tran KL, Zhang Z, Eisenberg E, Winnekeer RC, Osteen KG. Down-regulation of endometrial matrix metalloproteinase-3 and -7 expression in vitro and therapeutic regression of experimental endometriosis in vivo by a novel nonsteroidal progesterone receptor agonist, tanaproget. J Clin Endocrinol Metab 2006;91:1554-1560
36. Noble LS, Simpson ER, Johns A, Bulun SE. Aromatase expression in endometriosis. J Clin Endocrinol Metab 1996;81:174-179
37. Bulun SE, Yang S, Fang Z, Gurates B, Tamura M, Sebastian S. Estrogen production and metabolism in endometriosis. Ann N Y Acad Sci 2002;955:75-85.
38. Velasco I, Rueda J, Acién P. Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis. Mol Hum Reprod 2006;12:377-381 (Pubitemid 43985608)
39. Heilier JF, Donnez O, Van Kerckhove V, Lison D, Donnez J. Expression of aromatase (P450 aromatase/CYP19) in peritoneal and ovarian endometriotic tissues and deep endometriotic (adenomyotic) nodules of the rectovaginal septum. Fertil Steril 2006;85:1516-1518
40. Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril 2006;85:1307-1318
41. Takayama K, Zeitoun K, Gunby RT, Sasano H, Carr BR, Bulun SE. Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 1998 69:709-713 (Pubitemid 28188468)
42. Shippen ER, West WJ Jr. Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril 2004;81:1395-1398 (Pubitemid 38609330)
43. Soysal S, Soysal ME, Ozer S, Gul N, Gezgin T. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod 2004;19:160-167 (Pubitemid 38072026)
44. Amsterdam LL, Gentry W, Jobanputra S, Wolf M, Rubin SD, Bulun SE. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril 2005;84:300-304 (Pubitemid 41125248)
45. Hefler LA, Grimm C, van Trotsenburg M, Nagele F. Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. Fertil Steril 2005;84:1033-1036 (Pubitemid 41414604)
46. Ailawadi RK, Jobanputra S, Kataria M, Gurates B, Bulun SE. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril 2004;81:290-296 (Pubitemid 38223905)
47. Razzi S, Fava A, Sartini A, De Simone S, Cobellis L, Petraglia F. Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman. BJOG 2004;111:182-184 (Pubitemid 38186813)
48. Fatemi HM, Al-Turki HA, Papanikolaou EG, Kosmas L, De Sutter P, Devroey P. Successful treatment of an aggressive recurrent post-menopausal endometriosis with an aromatase inhibitor. Reprod Biomed Online 2005;11:455-457 (Pubitemid 41762064)
49. Mousa NA, Bedaiwy MA, Casper RF. Aromatase inhibitors in the treatment of severe endometriosis. Obstet Gynecol 2007;109:1421-1423
50. Remorgida V, Abbamonte HL, Ragni N, Fulcheri E, Ferrero S. Letrozole and norethisterone acetate in rectovaginal endometriosis. Fertil Steril 2007;88:724-726 (Pubitemid 47368251)
51. Remorgida V, Abbamonte LH, Ragni N, Fulcheri E, Ferrero S. Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis. Aust N Z J Obstet Gynaecol 2007;47:222-225
52. Yano S, Ikegami Y, Nakao K. Studies on the effect of the new non-steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats. Arzneimittel Forschung 1996;46:192-195
53. Kudoh M, Susaki Y, Ideyama Y, Nanya T, Mori M, Shikama H. Inhibitory effects of a novel aromatase inhibitor, YM511, in rats with experimental endometriosis. J Steroid Biochem Mol Biol 1997;63:1-3.
54. Purohit A, Fusi L, Brosens J, Woo LW, Potter BV, Reed MJ. Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy. Hum Reprod 2008;23:290-297 (Pubitemid 351651236)
55. Noble LS, Takayama K, Zeitoun KM, Putman JM, Johns DA, Hinshelwood MM et al. Clin Endocrinol Metab 1997;82:600-606
56. Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril 2006;85:1307-1318
57. Hasegawa K, Ohashi Y, Ishikawa K, Yasue A, Kato R, Achiwa Y, Nishio E et al. Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor. Int J Oncol 2005;26:1419-1428
58. Dogan E, Saygili U, Posaci C, Tuna B, Caliskan S, Altunyurt S et al. Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib. Fertil Steril 2004;82( Suppl 3):1115-1120
59. Matsuzaki S, Canis M, Darcha C, Dallel R, Okamura K, Mage G. Cyclooxygenase-2 selective inhibitor prevents implantation of eutopic endometrium to ectopic sites in rats. Fertil Steril 2004;82:1609-1615
60. Cobellis L, Razzi S, De Simone S, Sartini A, Fava A, Danero S et al. The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. Eur J Obstet Gynecol Reprod Biol 2004;116:100-102
61. Vonkeman HE, Brouwers JR, van de Laar MA. Understanding the NSAID related risk of vascular events. BMJ 2006;332:895-898
62. Gazvani R, Templeton A. Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction 2002;123:217-226
63. Barcz E, Rozewska ES, Kaminski P, Demkow U, Bobrowska K, Marianowski L. Angiogenic activity and IL-8 concentrations in peritoneal fluid and sera in endometriosis. Int J Gynaecol Obstet 2002;79:229-235
64. Mahnke JL, Dawood MY, Huang JC. Vascular endothelial growth factor and interleukin-6 in peritoneal fluid of women with endometriosis. Fertil Steril 2001;73:166-170
65. McLaren J, Prentice A, Charnock-Jones DS, Smith SK. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 1996;11:220-223 (Pubitemid 26047702)
66. Van Langendonckt A, Donnez J, Defrere S, Dunselman GAJ, Groothuis PG. Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises. Mol Hum Reprod 2008;14:259-268 (Pubitemid 351804027)
67. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Human Reprod Update 2000;6:45-55. (Pubitemid 30099342)
68. Nisolle M, Casanas-Roux F, Anaf V, Mine JM, Donnez J. Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil Steril 1993;59:681-684 (Pubitemid 23086336)
69. Hull ML, Charnock-Jones DS, Chan CL, Bruner-Tran KL, Osteen KG, Tom BD et al. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab 2003;88:2889-2899 (Pubitemid 36733546)
70. Nap AW, Griffioen AW, Dunselman GA, Bouma-Ter Steege JC, Thijssen VL, Evers JL, Groothuis PG. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab 2004;89:1089-1095
71. Becker CM, Sampson DA, Rupnick MA, Rohan RM, Efstathiou JA, Short SM et al. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril 2005;84(Suppl 2):1144-1155
72. Becker CM, Sampson DA, Short SM, Javaherian K, Folkman J, D'Amato RJ. Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Fertil Steril 2006;85:71-77 (Pubitemid 43063425)
73. Becker CM, Rohwer N, Funakoshi T, Cramer T, Bernhardt W, Birsner A et al. 2-Methoxyestradiol inhibits hypoxia-inducible factor-1α and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol 2008;172:534-544 (Pubitemid 351282038)
74. Nothnick WB, Curry TE Jr, Vernon MW. Immunomodulation of rat endometriotic implant growth and protein production. Am J Reprod Immunol 1994;31:151-162
75. Steinleitner A, Lambert H, Roy S. Immunomodulation with pentoxifylline abrogates macrophage-mediated infertility in an in vivo model: a paradigm for a novel approach to the treatment of endometriosis-associated subfertility. Fertil Steril 1991;55:26-31.
76. Balasch J, Creus M, Fábregues F, Carmona F, Martínez- Román S, Manau D et al. Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized clinical trial. Hum Reprod 1997;12:2046-2050 (Pubitemid 27462490)
77. Sinaii N, Cleary SD, Ballweg ML, Nieman LK, Stratton P. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. Hum Reprod 2002;17:2715-2724 (Pubitemid 35174127)
78. Ward A, Clissold SP. Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987;34:50-97.
79. Kamancic H, Thiel JA. Pentoxifylline after conservative surgery for endometriosis: a randomized, controlled trial. J Minim Invasive Gynecol 2008;15:62-66
80. Alborzi S, Ghotbi S, Parsanezhad ME, Dehbashi S, Alborzi S, Alborzi M. Pentoxifylline therapy after laparoscopic surgery for different stages of endometriosis: a prospective, double-blind, randomized, placebo-controlled study. J Minim Invasive Gynecol 2007;14:54-58
81. Alkharfy KM, Kellum JA, Matzke GR. Unintended immunomodulation: part II. Effects of pharmacological agents on cytokine activity. Shock 2000;13:346-360
82. Maksymowych WP, Avina-Zubieta A, Luong MH, Russell AS. An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J Rheumatol 1995;22:625-629
83. Reimund JM, Dumont S, Muller CD, Kenney JS, Kedinger M, Baumann R et al. In vitro effects of pentoxifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 1997;40:475-480
84. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP 3rd, Larrick J et al. Cellular and molecular regulation of tumor necrosis factor-alpha by pentoxifylline. Biochem Biophys Res Comm 1988;155:1230-1236
85. Sullivan GW, Carper HT, Novick WJ Jr, Mandell GL. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect Immun 1988;56:1722-1729
86. Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999;93:198-208.
87. Uygur D, Aytan H, Zergeroglu S, Batioglu S. Leflunomide -an immunomodulator - induces regression of endometrial explants in a rat model of endometriosis. J Soc Gynecol Investig 2006;13:378-383
88. Aytan H, Caglar P, Uygur D, Zergeroglu S, Batioglu S. Effect of the immunomodulator leflunomide on the induction of endometriosis in an experimental rat model. Fertil Steril 2007;87:698-701. (Pubitemid 46385952)
89. Jarvis B, Faulds D. Etanercept: A review of its use in rheumatoid arthritis. Drugs 1999;57:945-966 (Pubitemid 29313207)
90. Barrier BF, Bates GW, Leland MW, Leach DA, Robinson RD, Propst AM. Efficacy of anti-tumor necrosis factor therapy in treatment of spontaneous endometriosis in baboons. Fertil Steril 2004;81(Suppl 1):775-779
91. Markham A, Lamb HM. Infliximab: A review of its use in the management of rheumatoid arthritis. Drugs 2000;59:1341-1359 (Pubitemid 30410148)
92. Koninckx PR, Craessaerts M, Timmerman D, Cornillie F, Kennedy S. Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod 2008;23:2017-2023
93. Nikas SN, Drosos, AA. Onercept. Serono. Curr Opin Investig Drugs 2003;4:1369-1376
94. D'Antonio M, Martelli F, Peano S, Papoian R, Borrelli F. Ability of recombinant human TNF binding protein-1 (r-hTBP-1) to inhibit the development of experimentally induced endometriosis in rats. J Reprod Immunol 2000;48:81-98.
95. D'Hooghe TM, Cuneo S, Nugent N, Chai D, Deer F, Mwenda J. Recombinant human TNF binding protein (r-hTBP-1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo-and drug-controlled study. Fertil Steril 2001;76(Suppl 3):S1.
96. D'Hooghe TM, Nugent NP, Cuneo S, Chai DC, Deer F, Debrock S et al. Recombinant human TNFRSF1A (r-hTBP1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo- and drug-controlled study. Biol Report 2006;74:131-136
97. Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs 2004;18:121-139
98. Mezyk R, Bzowaka M, Bereta J. Structure and functions of tumor necrosis factor-alpha converting enzyme. Acta Biochimica Polonica 2003;50:625-645
99. Zhang Y, Xu J, Levin J, Hegen M, Li G, Robertshaw H et al. Identification and characterization of 4-[[4-(2-butynyloxy)phyenyl]sulfonyl]-N-hydroxy-2,2- dimethyl-(3S)-thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis. J Pharmacol Exp Ther 2004;309:348-355
100. Conway JG, Andrews RC, Beaudet B, Bickett DM, Boncek V, Brodie TA et al. Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rate by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases. J Pharmacol Exp Ther 2001;298:900-908
101. Gottschalk C, Malberg K, Arndt M. Matrix metalloproteinases and TACE play a role in the pathogenesis of endometriosis. Adv Exp Med Biol 2000;477:483-486